SCHEMBL30765683

SCHEMBL30765683

COC(=O)Cn1c(-c2ccccc2)ncc(NC(=O)c2ncc(-c3ccccc3)o2)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 1/20 0.47
TUBB P07437 1/20 0.47
TUBA3C P0DPH7 1/20 0.47
TUBA1B P68363 1/20 0.47
TUBA4A P68366 1/20 0.47
TUBB4B P68371 1/20 0.47
TUBB3 Q13509 1/20 0.47
TUBB2A Q13885 1/20 0.47
TUBB8 Q3ZCM7 1/20 0.47
TUBA3E Q6PEY2 1/20 0.47
TUBA1A Q71U36 1/20 0.47
TUBA1C Q9BQE3 1/20 0.47
TUBB6 Q9BUF5 1/20 0.47
TUBB2B Q9BVA1 1/20 0.47
TUBB1 Q9H4B7 1/20 0.47
ELANE P08246 9/20 0.47
WNT3A P56704 1/20 0.46
HDAC1 Q13547 4/20 0.43
HDAC6 Q9UBN7 4/20 0.43
CASP1 P29466 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30766127 0.90 TUBB4A (0.51) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL30765492 0.86 ELANE (0.49) ELANECASP1KDM4ESMN1; SMN2
SCHEMBL30765794 0.79 HDAC1 (0.46) ELANEWNT3AHDAC1HDAC6CASP1
SCHEMBL30765976 0.77 CASP1 (0.47) ELANECASP1
SCHEMBL30765564 0.77 ELANE (0.49) ELANECASP1SMN1; SMN2
SCHEMBL30765787 0.76 CASP1 (0.44) ELANECASP1KDM4ESMN1; SMN2
SCHEMBL30765989 0.75 KDM4E (0.51) ELANEKDM4ESMN1; SMN2
SCHEMBL30765866 0.75 HDAC2 (0.51) ELANEHDAC1HDAC6CASP1HDAC3
SCHEMBL6245424 0.75 ELANE (0.49) ELANECASP1KDM4ESMN1; SMN2
SCHEMBL30765438 0.74 KDM4E (0.50) ELANEKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed